Bros. Advisors Lp Baker Acquires 1,348,955 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Director Bros. Advisors Lp Baker purchased 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The shares were purchased at an average price of $116.32 per share, with a total value of $156,910,445.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

  • On Thursday, June 15th, Bros. Advisors Lp Baker purchased 660,779 shares of Alexion Pharmaceuticals stock. The shares were purchased at an average price of $117.33 per share, with a total value of $77,529,200.07.

Alexion Pharmaceuticals, Inc. (ALXN) opened at 116.16 on Tuesday. The stock’s 50 day moving average is $113.13 and its 200 day moving average is $122.38. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $145.41. The company has a market capitalization of $26.08 billion, a P/E ratio of 55.34 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.33. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. The business had revenue of $870 million during the quarter, compared to analysts’ expectations of $826.63 million. During the same period last year, the company posted $1.11 EPS. The business’s revenue was up 24.3% on a year-over-year basis. On average, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post $5.31 earnings per share for the current year.

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

TRADEMARK VIOLATION WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/2654434/bros-advisors-lp-baker-acquires-1348955-shares-of-alexion-pharmaceuticals-inc-alxn-stock.html.

Several institutional investors have recently modified their holdings of the company. Hudson Bay Capital Management LP purchased a new position in Alexion Pharmaceuticals during the fourth quarter worth approximately $12,847,000. DekaBank Deutsche Girozentrale boosted its position in Alexion Pharmaceuticals by 18.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 114,493 shares of the biopharmaceutical company’s stock worth $14,017,000 after buying an additional 17,642 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD boosted its position in Alexion Pharmaceuticals by 10.9% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 18,859 shares of the biopharmaceutical company’s stock worth $2,286,000 after buying an additional 1,849 shares in the last quarter. Baird Financial Group Inc. boosted its position in Alexion Pharmaceuticals by 219.0% in the first quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $1,771,000 after buying an additional 10,028 shares in the last quarter. Finally, LS Investment Advisors LLC boosted its position in Alexion Pharmaceuticals by 13.0% in the first quarter. LS Investment Advisors LLC now owns 6,131 shares of the biopharmaceutical company’s stock worth $743,000 after buying an additional 706 shares in the last quarter. 94.40% of the stock is owned by institutional investors and hedge funds.

A number of research firms have recently commented on ALXN. Nomura began coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 1st. They set a “buy” rating for the company. BMO Capital Markets restated an “outperform” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, May 1st. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Stifel Nicolaus restated a “buy” rating and set a $157.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Finally, Jefferies Group LLC set a $120.00 price target on shares of Alexion Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, June 8th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $161.38.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.